PHARMACOKINETIC INVESTIGATION OF REMOGLIFLOZIN IN RAT PLASMA SAMPLES BY HIGH-THROUGHPUT HPLC-MS-MS

Authors

  • RAVIKANTH INTURI Department of Chemistry, Krishna University, Machilipatnam, Andhra Pradesh, India https://orcid.org/0000-0002-0121-8779
  • MEDEPALLI DAVID RAJU Department of Chemistry, Krishna University, Machilipatnam, Andhra Pradesh, India
  • MANDAVA VENKATA BASAVESWARA RAO Department of Chemistry, Krishna University, Machilipatnam, Andhra Pradesh, India
  • SRIKANTH INTURI Department of Pharamaceutical Analysis, Narasaraopeta Institute of Pharmaceutical Sciences, Narasaraopet, Guntur, Andhra Pradesh 521001, India https://orcid.org/0000-0002-0121-8779

DOI:

https://doi.org/10.22159/ijap.2022v14i6.45700

Keywords:

Bio-analytical, Empagliflozin, HPLC-MS-MS, Internal standard, Remogliflozin, Wistar male Rat

Abstract

Objective: Remogliflozin (REMO), a selective inhibitor of the renal sodium-dependent glucose transporter 2 channel, which could increase urine glucose excretion and lower plasma glucose in humans. To establish a simple, sensitive and completely validated HPLC-MS-MS approach for the analysis of Remogliflozin in rat plasma samples.

Methods: The method was developed after simple step protein precipitation by acetonitrile and Empagliflozin (EMPA) was used as internal standard. Separation was done  on an CORTECS C18, 90 Å, 2.7 µm, 4.6 mm X 150 mm with an isocratic mobile phase consisting of 0.1% Formic acid : acetonitrile (20:80%, v/v) and pumped at a flow stream of 0.8 ml/min at ambient temperature.

Results: The approach developed showed fine calibration curve in the quantity range of 5-1000 pg/ml with correlation coefficient (r2) of ≥ 0.9997 and the intra-run accuracy and precision was 99.91 to 109.07% and 0.17 to 1.34, inter-run accuracy and precision was 99.8 to 101.54 and 0.17 to 1.66 according to FDA guidelines.

Conclusion: The newly designed and validated approach was simple, fast and applied effectively for single-dose oral pharmacokinetic investigation in Wistar male rats for the quantification of REMO in biological matrix.

Downloads

Download data is not yet available.

References

Garcia-Ropero A, Badimon JJ, Santos-Gallego CG. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Expert Opin Drug Metab Toxicol. 2018; 14(12):1287-1302. doi:10.1080/17425255.2018.1551877, PMID: 30463454.

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017; 377:644-657. doi:10.1056/NEJMoa1611925, PMID: 28605608.

Tang H, Cui W, Li D, Wang T, Zhang J, Zhai S, Song Y. Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017; 19(1):142-147. doi:10.1111/dom.12785, PMID: 27598833.

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE–TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019; 380:347-357. doi:10.1056/NEJMoa1812389, PMID: 30415602.

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med.2015; 373:2117-28. doi:10.1056/NEJMoa1504720, PMID: 26378978.

Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019; 393(10166):31-39. doi:10.1016/S0140-6736(18)32590-X, PMID: 30424892.

Santos-Gallego CG, Garcia-Ropero A, Mancini D, Pinney SP, Contreras JP, Fergus I, Abascal V, Moreno P, Atallah-Lajam F, Tamler R, Lala A, Sanz J, Fuster V, Badimon JJ. Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity? Cardiovasc Drugs Ther. 2019; 33(1):87-95. doi:10.1007/s10557-018-06850-0, PMID: 30675708.

Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, Flores E, Garcia-Ropero A, Sanz J, Hajjar RJ, Fuster V, Badimon JJ. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. J Am Coll Cardiol. 2019; 73(15):1931-1944. doi:10.1016/j.jacc.2019.01.056, PMID: 30999996.

Flores E, Santos-Gallego CG, Diaz-Mejía N, Badimon JJ. Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity? Cardiovasc Drugs Ther. 2018; 32:213-222. doi:10.1007/s10557-018-6786-x, PMID: 29679303.

Mikhail N. Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus. Expert Opin Investig Drugs. 2015; 24(10):1381-7. doi:10.1517/13543784.2015.1061501, PMID: 26288025.

Tammisetty MR, Challa BR, Puttagunta SB. A Novel Analytical Method for the Simultaneous Estimation of Remogliflozin and Metformin Hydrochloride by UPLC/PDA in Bulk and Formulation Application to the Estimation of Product Traces. Turk J Pharm Sci. 2021; 18(3):296-305. doi:10.4274/tjps.galenos.2020.39699, PMID: 34157819.

Attimarad, M.; Elgorashe, R.E.E.; Subramaniam, R.; Islam, M.M.; Venugopala, K.N.; Nagaraja, S.; Balgoname, A.A. Development and Validation of Rapid RP-HPLC and Green Second-Derivative UV Spectroscopic Methods for Simultaneous Quantification of Metformin and Remogliflozin in Formulation Using Experimental Design. Separations 2020; 7(4):59. doi:10.3390/separations7040059.

Attimarad M, Nair AB, Nagaraja S, Aldhubiab BE, Venugopala KN, Pottathil S. Smart UV Derivative Spectrophotometric Methods for Simultaneous Determination of Metformin and Remogliflozin: Development, Validation and Application to the Formulation. Indian J of Pharmaceutical Education and Research. 2021; 55(1s):s293-s302. doi:10.5530/ijper.55.1s.62.

Attimarad M, Nair AB, Sreeharsha N, Al-Dhubiab BE, Venugopala KN, Shinu P. Development and Validation of Green UV Derivative Spectrophotometric Methods for Simultaneous Determination Metformin and Remogliflozin from Formulation: Evaluation of Greenness. Int J Environ Res Public Health. 2021; 18(2):448. doi:10.3390/ijerph18020448, PMID: 33429964.

Dave Vidhi, Paresh Patel. Method development and Validation of UV Spectrophotometric estimation of Remogliflozin Etabonate in bulk and its tablet dosage form. Research Journal of Pharmacy and Technology. 2021; 14(4):2042-4. doi:10.52711/0974-360X.2021.00362.

Dimal A. Shah, Ishita I. Gondalia, Vandana B. Patel, Ashok Mahajan and Usmangani K. Chhalotiya. Stability indicating liquid chromatographic method for the estimation of remogliflozin etabonate. J. Chem. Metrol. 2020; 14(2):125-132. doi:10.25135/jcm.46.20.07.1734.

Shah, D.A., Gondalia, I.I., Patel, V.B., Mahajan A, Chhalotiya U, Nagda, D.C. Stability indicating thin-layer chromatographic method for estimation of antidiabetic drug Remogliflozin etabonate. Futur J Pharm Sci 2021; 7:83. doi:10.1186/s43094-021-00230-6.

M. Satya Venkata Sakuntala, A. Lakshmana Rao, M. William Carey. Simultaneous estimation of ivacaftor and tezacaftor in rat plasma by Liquid chromatography coupled with tandem-mass-spectrometry: Application to pharmacokinetic studies. Thai Journal of Pharmaceutical Sciences 2021; 45(6): 451-460.

U.S. Food and Drug Administration Guidance for Industry: Bioanalytical Method Validation (2018) U.S. Department of Health and Human Services, Food and Drug Administration. Accessed 29 Jan 2021

U.S. Food and Drug Administration Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products—General Considerations (2002) U.S. Department of Health and Human Services, Food and Drug Administration. Accessed 09 June 2021

U.S. Food and Drug Administration Guidance for Industry: Food-effect Bioavailability and Fed Bio Equivalence Studies (2002) U.S. Department of Health and Human Services, Food and Drug Administration. Accessed 09 June 2021

Srikanth Inturi, Prameela Rani Avula. A sensitive bioanalytical method development and validation of cabozantinib in human plasma by LC-ESI-MS/MS. Braz. J. Pharm. Sci. 2018; 54(2):e17163. doi:10.1590/s2175-97902018000217163.

Venkata Suresh Ponnuru, B.R. Challa, Ramarao Nadendla. Quantification of desloratadine in human plasma by LC-ESI-MS/MS and application to a pharmacokinetic study. J Pharm Anal. 2012; 2(3):180-187. doi:10.1016/j.jpha.2012.01.008.

Yahdiana Harahap, Innet Maysyarah, Herman Suryadi. Analytical Validation of Clopidogrel in Human Plasma through Ultra high performance Liquid Chromatography-Tandem Mass Spectrometry. Int J App Pharm. 2017; 9:163-167. doi:10.22159/ijap.2017.v9s1.79_86.

Srikanth I and Prameela Rani A. Development and validation of liquid chromatography coupled with tandem mass spectrometry method for estimation of lenvatinib in human plasma. Asian Journal of Pharmaceutical and Clinical Research. 2017; 10(7):120-6. doi:10.22159/ajpcr.2017.v10i7.18287.

Agbokponto, J. E., L. A. Yemoa, A. G. Assanhou, R. Liu, H. Ganfon, and L. Ding. Liquid Chromatography Tandem Mass Spectrometry Determination Method of Bencycloquidium Bromide: Application to Drug interaction Study in Human. International Journal of Pharmacy and Pharmaceutical Sciences. 2021; 13(10):43-46. doi:10.22159/ijpps.2021v13i10.5791.

Halder, D., S. Das, B. Ghosh, E. Biswas, S. Roy, A. Bose, N. Singh, And T. K. Pal. “An LC-MS/MS based Bioanalytical approach to resolve Pharmacokinetic Investigation of Acotiamide Hydrochloride and its Application to Bioequivalence Study”. International Journal of Pharmacy and Pharmaceutical Sciences. 2020; 12(10):76-84. doi:10.22159/Ijpps.2020v12i10.38410.

Published

08-09-2022

How to Cite

INTURI, R., RAJU, M. D., BASAVESWARA RAO, M. V., & INTURI, S. (2022). PHARMACOKINETIC INVESTIGATION OF REMOGLIFLOZIN IN RAT PLASMA SAMPLES BY HIGH-THROUGHPUT HPLC-MS-MS. International Journal of Applied Pharmaceutics, 14(6). https://doi.org/10.22159/ijap.2022v14i6.45700

Issue

Section

Original Article(s)